Novo Nordisk on seeking partnerships to expand its portfolio
Its vast experience in diabetes and the amount of data collected has propelled Novo Nordisk into exploring new modalities and searching for valuable collaborators, according to the company’s senior VP of global drug discovery Karin Conde-Knape.
She discusses which therapeutic areas the company is gaining momentum in and how it aims to build its presence within these areas through external partnerships, in a session at the recent BIO-Europe with pharmaphorum’s founder Paul Tunnah.
Conde-Knape’s diverse work history started with her pharmaceutical career at Roche then shifted into business development at J&J, which she says expanded her horizons into how pharma views internal versus external research.
In her current role at Novo Nordisk, she applies that knowledge by focusing on research and exploring what can be done internally to build external relationships that produce valuable collaborations. She also recently started her PhD and postdoc in the US in cholesterol metabolism.
In the video below from BIO-Europe, she also talks about the successful collaborations Novo Nordisk has already established, the value of having a digital component in drug discovery, and how well-positioned the company is to engage in the next generation of treatments.
- Karin Conde-Knape is senior VP of global drug discovery, Novo Nordisk
- Paul Tunnah is chief content officer and managing director UK, Healthware Group and founder of pharmaphorum